Biocartis NV
Industry
- Biotechnology
- Pharmacogenetics-Pharmacogenomics
- In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Other Names/Subsidiaries
- Biocartis Group NV
Latest on Biocartis NV
Having focused its efforts on developing and commercializing oncology tests since 2017, Biocartis NV has reached an “inflection point,” according to its CEO, and is moving into infectious disease di
The European Investment Bank (EIB) has granted a loan of €24m to F2G Ltd. , the UK-based antifungal development company that was spun out of the University of Manchester in the early 2000s and which
[ Editor's note: This is the second of a two-part series on the liquid biopsy market. Check out the first article, providing a market overview a look at some of the larger players, here . ] Dozens o
Device Transactions Device fundraising in Q4 2017 totaled $2.6 billion, the highest single-quarter value of the year. However, total 2017 financing for the industry declined from 2016: $8.4 billion in